HeartBeat.bio is a drug discovery company dedicated to developing a high-throughput human organoid screening platform for cardiac drug discovery. The technology platform is built on the worldwide first, self-organizing, highly scalable cardiac organoids (Cardioids) which uniquely recapitulate the physiology of human heart chambers and enable modeling of diseases such as drug-induced and genetic cardiomyopathies as well as myocardial infarction and fibrosis. The Cardioid-based screening platform will lead to more relevant drug candidates and thus significantly reduce time and cost of cardiac drug development.

We are a bunch of scientists and industry experts with diverse backgrounds, different nationalities but a common goal!